News

The two companies had intended to submit a supplemental biologics license application (sBLA) for Erbitux (cetuximab) as a single agent and in combination with radiation in squamous cell

Lactin-V, a capsule containing a natural human bacterial organism, will be studied in a total of eight centers for recurrent urinary tract infection (RUTI) and recurrent bacterial vaginosis

Provectus is preparing the FDA filing to commence the trials and expects to begin clinical studies for psoriasis in late 2005 and eczema in 2006. The company has

The results were published by Dr Beverly Davidson of the University of Iowa, an academic collaborator of Sirna, Targeted Genetics’ partner for the development of novel therapies for

GTI-2040 is a highly specific inhibitor of R2, a component of ribonucleotide reductase, which can behave as a malignant determinant for cancer growth and metastasis, and is abnormally

The effects were found to be significantly better than placebo and comparable to that of an approved atypical antipsychotic agent. No serious adverse events attributable to ocaperidone were

Rotateq is Merck’s investigational vaccine to protect against rotavirus gastroenteritis. It is an oral, liquid vaccine that contains five human serotypes – G1, G2, G3, G4 and P1.

The phase II trial will further assess the ability of D-63153, a fourth generation LHRH (luteinizing hormone releasing hormone) antagonist, to suppress testosterone levels in a dose-dependent manner

The company’s efforts will focus on the recent FDA-approved label change, based on a landmark four-year study, indicating that weight loss with Xenical (orlistat) reduces the risk of